Advertisement
EVGN vs FBIOP
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVGN is a Hold and FBIOP is a Hold.
EVGN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 24, 2026
EVGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 45 cases where EVGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EVGN's RSI Oscillator exited the oversold zone, 36 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for EVGN just turned positive on October 15, 2026. Looking at past instances where EVGN's MACD turned positive, the stock continued to rise in 38 of 48 cases over the following month. The odds of a continued upward trend are 79%.
Following a +2.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVGN advanced for three days, in 142 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EVGN as a result. In 81 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for EVGN entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.855) is normal, around the industry mean (2.835). P/E Ratio (-0.522) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (3.012) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. EVGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
FBIOP in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 06, 2026
FBIOP broke above its upper Bollinger Band on October 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 35 similar instances where the stock broke above the upper band. In 28 of the 35 cases the stock fell afterwards. This puts the odds of success at 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FBIOP as a result. In 63 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
The Moving Average Convergence Divergence Histogram (MACD) for FBIOP turned negative on October 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In 24 of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
FBIOP moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FBIOP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
The Aroon Indicator for FBIOP entered a downward trend on October 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FBIOP's RSI Oscillator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +10.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where FBIOP advanced for three days, in 196 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. FBIOP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (2.835). P/E Ratio (0.000) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.047) settles around the average of (135.264) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FBIOP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
EVGN | FBIOP | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 43 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 89 | 38 | |
P/E GROWTH RATING 1..100 | 31 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EVGN's Valuation (24) in the Biotechnology industry is in the same range as FBIOP (43) in the null industry. This means that EVGN’s stock grew similarly to FBIOP’s over the last 12 months.
EVGN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as FBIOP (100) in the null industry. This means that EVGN’s stock grew similarly to FBIOP’s over the last 12 months.
EVGN's SMR Rating (100) in the Biotechnology industry is in the same range as FBIOP (100) in the null industry. This means that EVGN’s stock grew similarly to FBIOP’s over the last 12 months.
FBIOP's Price Growth Rating (38) in the null industry is somewhat better than the same rating for EVGN (89) in the Biotechnology industry. This means that FBIOP’s stock grew somewhat faster than EVGN’s over the last 12 months.
EVGN's P/E Growth Rating (31) in the Biotechnology industry is significantly better than the same rating for FBIOP (100) in the null industry. This means that EVGN’s stock grew significantly faster than FBIOP’s over the last 12 months.
| EVGN | FBIOP | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 84% | 4 days ago 87% |
| Stochastic ODDS (%) | 4 days ago 82% | 4 days ago 71% |
| Momentum ODDS (%) | 4 days ago 88% | 4 days ago 65% |
| MACD ODDS (%) | 4 days ago 79% | 4 days ago 67% |
| TrendWeek ODDS (%) | 4 days ago 75% | 4 days ago 71% |
| TrendMonth ODDS (%) | 4 days ago 90% | 4 days ago 72% |
| Advances ODDS (%) | 7 days ago 72% | 14 days ago 67% |
| Declines ODDS (%) | 11 days ago 90% | 6 days ago 72% |
| BollingerBands ODDS (%) | 4 days ago 84% | 4 days ago 80% |
| Aroon ODDS (%) | 4 days ago 90% | 4 days ago 75% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EVGN’s FA Score shows that 2 FA rating(s) are green while FBIOP’s FA Score has 0 green FA rating(s).
- EVGN’s FA Score: 2 green, 3 red.
- FBIOP’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EVGN’s TA Score shows that 5 TA indicator(s) are bullish while FBIOP’s TA Score has 3 bullish TA indicator(s).
- EVGN’s TA Score: 5 bullish, 3 bearish.
- FBIOP’s TA Score: 3 bullish, 6 bearish.
Price Growth
EVGN (@Biotechnology) experienced а +1.05% price change this week, while FBIOP (@Biotechnology) price change was -6.67% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.93%. For the same industry, the average monthly price growth was -18.74%, and the average quarterly price growth was -19.71%.
Reported Earning Dates
EVGN is expected to report earnings on Nov 18, 2026.
Industries' Descriptions
@Biotechnology (-7.93% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
EVGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, EVGN has been loosely correlated with NCNA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if EVGN jumps, then NCNA could also see price increases.
| Ticker / NAME | Correlation To EVGN | 1D Price Change % | ||
|---|---|---|---|---|
| EVGN | 100% | -3.01% | ||
| NCNA - EVGN | 43% Loosely correlated | -2.93% | ||
| INSM - EVGN | 30% Poorly correlated | -2.96% | ||
| AXON - EVGN | 30% Poorly correlated | -6.45% | ||
| AURA - EVGN | 28% Poorly correlated | -3.79% | ||
| ARRY - EVGN | 28% Poorly correlated | -3.92% | ||
More | ||||
FBIOP and
Correlation & Price change
A.I.dvisor tells us that FBIOP and RADX have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that FBIOP and RADX's prices will move in lockstep.
| Ticker / NAME | Correlation To FBIOP | 1D Price Change % | ||
|---|---|---|---|---|
| FBIOP | 100% | -0.60% | ||
| RADX - FBIOP | 29% Poorly correlated | -4.63% | ||
| VNDA - FBIOP | 28% Poorly correlated | -4.95% | ||
| EVGN - FBIOP | 26% Poorly correlated | -3.01% | ||
| NKTR - FBIOP | 25% Poorly correlated | -5.14% | ||
| PTGX - FBIOP | 24% Poorly correlated | -5.71% | ||
More | ||||